Analysts Issue Forecasts for Repligen FY2024 Earnings

Repligen Co. (NASDAQ:RGEN - Free Report) - Equities research analysts at Leerink Partnrs issued their FY2024 earnings per share (EPS) estimates for Repligen in a note issued to investors on Tuesday, November 12th. Leerink Partnrs analyst P. Souda anticipates that the biotechnology company will earn $1.55 per share for the year. The consensus estimate for Repligen's current full-year earnings is $1.44 per share. Leerink Partnrs also issued estimates for Repligen's Q4 2024 earnings at $0.39 EPS, Q1 2025 earnings at $0.39 EPS, Q2 2025 earnings at $0.47 EPS, Q3 2025 earnings at $0.42 EPS, Q4 2025 earnings at $0.52 EPS, FY2025 earnings at $1.80 EPS and FY2026 earnings at $2.47 EPS.

A number of other brokerages have also commented on RGEN. StockNews.com raised shares of Repligen from a "sell" rating to a "hold" rating in a research report on Wednesday. Stephens reaffirmed an "overweight" rating and set a $170.00 price objective on shares of Repligen in a research report on Tuesday, July 30th. Wolfe Research began coverage on shares of Repligen in a research report on Thursday. They set a "peer perform" rating for the company. UBS Group cut their price objective on shares of Repligen from $205.00 to $185.00 and set a "buy" rating for the company in a research report on Wednesday, July 31st. Finally, Benchmark reissued a "hold" rating on shares of Repligen in a research note on Monday, August 5th. Four analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat.com, Repligen presently has a consensus rating of "Moderate Buy" and an average price target of $190.25.

Repligen Stock Performance

Repligen stock traded down $17.70 on Friday, reaching $124.73. 1,915,115 shares of the stock were exchanged, compared to its average volume of 665,967. The stock has a market cap of $6.99 billion, a PE ratio of -337.10, a PEG ratio of 4.36 and a beta of 0.96. The company has a current ratio of 6.65, a quick ratio of 5.56 and a debt-to-equity ratio of 0.26. Repligen has a twelve month low of $113.50 and a twelve month high of $211.13. The firm has a fifty day moving average price of $141.54 and a two-hundred day moving average price of $144.77.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.92%. The business had revenue of $154.87 million for the quarter, compared to analysts' expectations of $153.34 million. During the same period in the previous year, the company posted $0.23 EPS. Repligen's revenue was up 9.7% on a year-over-year basis.

Insider Transactions at Repligen

In other Repligen news, Director Anthony Hunt sold 22,191 shares of the company's stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the transaction, the director now directly owns 139,840 shares in the company, valued at approximately $20,328,540.80. This represents a 13.70 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.20% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Repligen

Several large investors have recently modified their holdings of the company. Champlain Investment Partners LLC boosted its stake in Repligen by 149.0% during the third quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company's stock worth $211,464,000 after acquiring an additional 850,345 shares in the last quarter. Thrivent Financial for Lutherans boosted its stake in Repligen by 240.5% during the second quarter. Thrivent Financial for Lutherans now owns 601,829 shares of the biotechnology company's stock worth $75,866,000 after acquiring an additional 425,061 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Repligen by 21.0% during the second quarter. Bank of New York Mellon Corp now owns 1,370,375 shares of the biotechnology company's stock worth $172,749,000 after acquiring an additional 237,884 shares in the last quarter. Conestoga Capital Advisors LLC boosted its stake in Repligen by 26.7% during the second quarter. Conestoga Capital Advisors LLC now owns 946,877 shares of the biotechnology company's stock worth $119,363,000 after acquiring an additional 199,322 shares in the last quarter. Finally, DF Dent & Co. Inc. boosted its stake in Repligen by 31.0% during the third quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company's stock worth $87,852,000 after acquiring an additional 139,615 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.